TAK · NYSE, OTC · CIK 0001395064

TAKEDA PHARMACEUTICAL CO LTD

TAKEDA PHARMACEUTICAL CO LTD’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 15, 2026. In fiscal 2025 (year ended Mar 31, 2025) it reported revenue of JPY 4.58T and net income of JPY 108.1B, according to its XBRL data on EDGAR. Its EDGAR record lists 53 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
JPY 4.58T
Net income, FY2025
JPY 108.1B
Form 4 filings on record, past 12 months
53

Company overview

Legal name (as filed)
TAKEDA PHARMACEUTICAL CO LTD
Tickers
TAK, TKPHF
SEC Central Index Key (CIK)
0001395064
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
TOKYO, Japan
State or country of incorporation
—
Fiscal year ends
—
SEC filer category
Large accelerated filer
Position in SEC ticker list
#260 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from TAKEDA PHARMACEUTICAL CO LTD’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in JPY; the fiscal year is named for the calendar year in which it ends.

Revenue
JPY 3.20TFY2021JPY 3.57TFY2022JPY 4.03TFY2023JPY 4.26TFY2024JPY 4.58TFY2025
Net income
JPY 376.2BFY2021JPY 230.2BFY2022JPY 317.0BFY2023JPY 144.2BFY2024JPY 108.1BFY2025
TAK annual results
ItemFY2021
ended Mar 31, 2021		FY2022
ended Mar 31, 2022		FY2023
ended Mar 31, 2023		FY2024
ended Mar 31, 2024		FY2025
ended Mar 31, 2025
RevenueJPY 3.20TJPY 3.57TJPY 4.03TJPY 4.26TJPY 4.58T
Net incomeJPY 376.2BJPY 230.2BJPY 317.0BJPY 144.2BJPY 108.1B
Diluted EPSJPY 238.96JPY 145.87JPY 201.94JPY 91.16JPY 67.23
Total assetsJPY 12.91TJPY 13.18TJPY 13.96TJPY 15.11TJPY 14.25T
Cash and equivalentsJPY 335.0BJPY 389.1BJPY 229.6BJPY 205.2BJPY 233.7B

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

TAK latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Jun 17, 202620-FAnnual report of a foreign private issuer· period Mar 31, 2026Document · Index
Sep 14, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about TAKEDA PHARMACEUTICAL CO LTD, by form type:

4 ×19144 ×176-K ×4
TAK recent filings
FiledFormWhat it isOriginal
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 14, 2026Document · Index
Sep 14, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 10, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 3, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 2, 2026Document · Index
Sep 2, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 31, 20266-KReport of a foreign private issuer· period Aug 28, 2026Document · Index
Aug 21, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 19, 2026Document · Index
Aug 19, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 18, 2026Document · Index
Aug 14, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 10, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 20266-KReport of a foreign private issuer· period Aug 5, 2026Document · Index
Jul 30, 20266-KReport of a foreign private issuer· period Jul 30, 2026Document · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

53 Form 4 filings appear in TAKEDA PHARMACEUTICAL CO LTD’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001395064 and XBRL company facts. TAKEDA PHARMACEUTICAL CO LTD on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.